07:23 AM EST, 11/10/2026 (MT Newswires) -- BofA Global Research reiterated Bayer's (BAYN.F) buy rating after the German life science company secured US regulatory approval for its asundexian drug in secondary stroke prevention. "Bayer's [Factor XIa] asundexian has been approved in US with a good label; 1) broad initiation window specifying 'recent stroke'; 2) no limit to duration therapy; 3) bleed risk not even included in label highlights (though reflected in full label but only as adverse reaction and not warning / precaution). Price also in line expectation at c$9k/year, 30% premium Xarelto but not upside case possible, likely to drive access)," analysts said Tuesday. "We believe PIII data is very strong (26% benefit on ischemic stroke vs no increase in bleeding, HR 1.10) and expect good adoption." Peak sales for asundexian are projected to reach 3 billon euros, driving the research firm's estimated pharmaceutical sales compound annual growth rate of 7%, with further upside potential to as high as 7 billion euros under a best-case scenario. "Any competitor slip-up remains upside to our numbers. We believe asundexian SSP data is a high bar (26% reduction inischemic stroke vs no increase in bleeding, HR 1.10). In [stroke prevention in atrial fibrillation], data likely needs to show stroke HR <1.1 & 30-40% reduction in ISTH major bleeds; 2) Return to better underlying cash flow on litigation resolution, with FY27 guide a key focus, where we see Eur3-5bn potential midterm vs low FCF generation of recent years," BofA added. The research firm has a price objective of 58 euros on Bayer's stock.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.